



UNIVERSITY OF LEEDS

This is a repository copy of *Genome-wide Association Study of Response to Methotrexate in Early Rheumatoid Arthritis Patients*.

White Rose Research Online URL for this paper:  
<http://eprints.whiterose.ac.uk/128128/>

Version: Accepted Version

---

**Article:**

Taylor, JC [orcid.org/0000-0002-2518-5799](https://orcid.org/0000-0002-2518-5799), Bongartz, T, Massey, J et al. (37 more authors) (2018) Genome-wide Association Study of Response to Methotrexate in Early Rheumatoid Arthritis Patients. *The Pharmacogenomics Journal*, 18 (4). pp. 528-538. ISSN 1470-269X

<https://doi.org/10.1038/s41397-018-0025-5>

---

(c) 2018, Macmillan Publishers Limited, part of Springer Nature. This is an author produced version of a paper published in the *Pharmacogenomics Journal*. Uploaded in accordance with the publisher's self-archiving policy.

**Reuse**

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.



[eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk)  
<https://eprints.whiterose.ac.uk/>

**Table 1.** Summary of the demographics and clinical characteristics for the patients included in the analysis for Phase 1 and 2.

Study	Sample Origin	N	Age (years)		Female		RF positive		Mean	MTX Starting Dose (mg)		Baseline DAS28	
			Mean	(SD)	N	(%)	N	(%)	Duration < 1 year	Min	Max	Mean	(SD)
<b>Phase 1</b>													
YEAR	UK	343	58.3	(13.1)	239	(70)	243	(73)	Yes	5	22.5	5.0	(1.2)
TEAR <sup>a</sup>	US	117	49.8	(12.0)	91	(66)	118	(86)	Yes	2.5	10	5.6	(1.0)
SWEFOT	Sweden	325	53.9	(14.0)	233	(71)	225	(69)	Yes	10	10	5.1	(0.9)
Netherlands	Netherlands	38	54.7	(12.2)	26	(68)	22	(58)	Yes	7.5	20	4.6	(1.2)
RAMS	UK	274	56.8	(14.1)	190	(69)			Yes	2.5	25	4.4	(1.2)
IDEA	UK	29	54.6	(12.0)	24	(69)	24	(71)	Yes	10	15	4.9	(1.3)
IACON	UK	128	59.5	(13.5)	91	(66)	78	(59)	Yes	5	25	4.3	(1.3)
EMPIRE	UK	22	53.1	(12.8)	17	(74)	14	(61)	Yes	10	10	4.2	(0.9)
CARDERA Trials <sup>a</sup>	UK	148	54.4	(12.9)	108	(67)	101	(68)	Yes	7.5	7.5	5.8	(1.1)
<b>Phase 2a</b>													
SERA	UK	429	58.4	(13.2)	279	(65)	169 <sup>b</sup>	(65)	No <sup>c</sup>	5	30	4.8	(1.2)
<b>Phase 2b</b>													
AMBITION	International	85	52.5	(13.8)	69	(74)	62	(67)	No	7.5	7.5	6.0	(0.8)
MabThera Trials	International	32	49.6	(12.5)	23	(72)	29	(91)	No	7.5	7.5	5.7	(0.9)
Ocrelizumab Trials	International	60	51.7	(11.1)	42	(70)	55	(92)	No	7.5	7.5	6.0	(0.9)

Abbreviations: DAS28, disease activity score in 28 joints (3 component CRP version); RF, Rheumatoid Factor; SD, standard deviation. <sup>a</sup> CRP not available, DAS28 calculated using ESR. <sup>b</sup> Data available for 262 samples. <sup>c</sup> Median symptom duration 172 days.